Suppr超能文献

利托那韦对人体 CYP3A 抑制的浓度效应关系。

Concentration effect relationship of CYP3A inhibition by ritonavir in humans.

机构信息

Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.

出版信息

Eur J Clin Pharmacol. 2013 Oct;69(10):1795-800. doi: 10.1007/s00228-013-1530-8. Epub 2013 Jun 9.

Abstract

PURPOSE

To investigate the dose and concentration dependency of CYP3A inhibition by ritonavir using the established limited sampling strategy with midazolam for CYP3A activity.

METHODS

An open, fixed-sequence study was carried out in 12 healthy subjects. Single ascending doses of ritonavir (0.1-300 mg) were evaluated for CYP3A inhibition in two cohorts using midazolam as a marker substance.

RESULTS

Ritonavir administered as a single oral dose produced a dose-dependent CYP3A inhibition with an ID50 of 3.4 mg. Using the measured ritonavir concentrations an exposure-inhibition effect curve was established with an IC50 of 600 h pmol/L (AUC2-4). Over the ritonavir dose range studied non-linear exposure of ritonavir was observed.

CONCLUSIONS

Ritonavir shows a dose and concentration effect relationship of CYP3A inhibition. In addition, a proposed auto-inhibition of ritonavir metabolism resulted in a non-linear exposure of ritonavir with sub-proportional concentrations at low doses. A time-dependent CYP3A activity may result when inhibitors of CYP3A with short elimination half-lives are used.

摘要

目的

利用已建立的咪达唑仑有限采样策略来研究利托那韦对 CYP3A 活性的抑制作用的剂量和浓度依赖性。

方法

在 12 名健康受试者中进行了一项开放、固定序列的研究。使用咪达唑仑作为标记物,在两个队列中评估了利托那韦(0.1-300mg)的单递增剂量对 CYP3A 的抑制作用。

结果

利托那韦单剂量口服给药产生剂量依赖性 CYP3A 抑制,ID50 为 3.4mg。使用测得的利托那韦浓度,建立了以 IC50 为 600 h pmol/L(AUC2-4)为特征的暴露-抑制效应曲线。在所研究的利托那韦剂量范围内,观察到非线性暴露利托那韦。

结论

利托那韦显示出 CYP3A 抑制的剂量和浓度效应关系。此外,利托那韦代谢的自动抑制导致低剂量时非比例浓度的非线性暴露。当使用半衰期短的 CYP3A 抑制剂时,可能会导致 CYP3A 活性的时间依赖性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验